University of Minnesota Medical Center Launches First-Ever Study of Novel Treatment for Symptoms of Peripheral Neuropathy
Photobiomodulation therapy developed by Twin Cities-based Realief Neuropathy Centers
MINNEAPOLIS, Minn. — (May 22, 2014) Realief Neuropathy Centers announced today that it has begun patient enrollment in the first-ever clinical study to assess the symptom relief effectiveness of Realief Therapy for patients with chemotherapy-induced peripheral neuropathy (CIPN). The University of Minnesota Medical Center Oncology Department is conducting the study.
Peripheral Neuropathy (PN) is one of the most prevalent chronic, progressive and debilitating diseases in the US, and it can be triggered by diabetes, chemotherapy, dialysis, alcohol abuse, Lyme’s disease and exposure to toxins. The current study will test the new therapy on patients who have contracted PN during chemotherapy treatments for ovarian cancer. Realief Therapy was developed by Twin Cities-based Realief Neuropathy Centers. It employs patient-specific use of a titrated Class IV therapeutic laser to restore nerve function, along with physiotherapy to address non- neurologic issues that are commonly associated with peripheral neuropathy. Laser titration is done by algorithms that adjust each treatment for a wide variety of real-time patient specific parameters to ensure an optimal photon exposure to nerve tissue. There are no reported adverse side effects of this therapy.
Neurotoxicity is recognized as a major symptomatic side effect of cisplatin- and paclitaxel-based chemotherapy — the standard treatment program for ovarian cancer. Chemotherapy-induced peripheral neuropathy, like all other forms of PN, typically begins in the feet or hands and progresses centrally. The symptoms may include any or all of the following: numbness, pain, tingling, paresthesia, loss of muscle function, loss of proprioception, and issues with balance. These symptoms can affect both waking and sleeping hours, leading to degradation of a patient’s work, home and social life.
Dr. Peter Argenta, Interim Division Director of Gynecologic Oncology at the University of Minnesota Medical Center, will be leading the study. In 2013, Dr. Argenta saw a number of his chemotherapy patients get significant relief of CIPN symptoms from a novel laser- based therapy developed by Realief Neuropathy Centers. Because he had not seen
outcomes like this from other types of treatments, he began looking at the extensive patient registry data for Realief Therapy, and determined that the potential value for patients warranted a prospective study.
“I have seen a good number of patients with chemo-induced peripheral neuropathy, and they continue to suffer significant declines in their quality of life because there are no satisfactory treatments,” said Argenta. “But if this randomized, double blind, placebo controlled study results in outcomes similar to the retrospective data we’ve examined, this therapy could be a very important breakthrough for chemotherapy patients.”
The therapy had it origins in the work of Realief Neuropathy Centers, which eventually led to the creation of the patent-pending therapy to mitigate symptoms that is offered by Realief Neuropathy Centers in several U.S. clinics. “We consistently see very significant improvements over the current standard of care for peripheral neuropathy following this therapy,” said Philip Walter, Realief’s CEO. “In addition, we are starting to see very high interest from physicians who have now seen their patients find relief from serious and debilitating symptoms.”
About Realief Neuropathy Centers
Realief Neuropathy Centers is a Minnesota company dedicated to developing effective non-invasive, non-pharmacologic therapies to mitigate the symptoms of chronic nerve
disease and damage. The company’s Realief Therapy is currently available for patients in Minnesota, Wisconsin, Arizona and South Carolina. For more information, call 800 298–6643 or go to www.realiefcenters.com